Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

被引：0
|
作者：
Viale, G [1 ]
Regan, M [1 ]
Dell'Orto, P [1 ]
Del Curto, B [1 ]
Braye, S [1 ]
Orosz, Z [1 ]
Brown, R [1 ]
Olszewski, WP [1 ]
Knox, F [1 ]
Oehlschlegel, C [1 ]
Thürlimann, B [1 ]
机构：
[1] BIG 1 98 Collaborat Int Breast Canc Study Grp, Bern, Switzerland
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S13 / S14
页数：2
相关论文
共 50 条
  • [21] Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer
    Giobbie-Hurder, Anita
    Price, Karen N.
    Gelber, Richard D.
    CLINICAL TRIALS, 2009, 6 (03) : 272 - 287
  • [22] Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
    Phillips, Kelly-Anne
    Aldridge, Julie
    Ribi, Karin
    Sun, Zhuoxin
    Thompson, Alastair
    Harvey, Vernon
    Thuerlimann, Beat
    Cardoso, Fatima
    Pagani, Olivia
    Coates, Alan S.
    Goldhirsch, Aron
    Price, Karen N.
    Gelber, Richard D.
    Bernhard, Juerg
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) : 221 - 226
  • [23] Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
    Kelly-Anne Phillips
    Julie Aldridge
    Karin Ribi
    Zhuoxin Sun
    Alastair Thompson
    Vernon Harvey
    Beat Thürlimann
    Fatima Cardoso
    Olivia Pagani
    Alan S. Coates
    Aron Goldhirsch
    Karen N. Price
    Richard D. Gelber
    Jürg Bernhard
    Breast Cancer Research and Treatment, 2011, 126 : 221 - 226
  • [24] Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
    Buechler, Steven A.
    Gray, Kathryn P.
    Gokmen-Polar, Yesim
    Willis, Scooter
    Thuerlimann, Beat
    Kammler, Rosita
    Viale, Giuseppe
    Leyland-Jones, Brian
    Badve, Sunil S.
    Regan, Meredith M.
    JNCI CANCER SPECTRUM, 2019, 3 (04)
  • [25] Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial
    Ribi, K. E.
    Phillips, K. A.
    Sun, Z.
    Stephens, A.
    Thompson, A.
    Harvey, V.
    Thuerlimann, B.
    Cardoso, F.
    Coates, A. S.
    Bernhard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer
    Thuerlimann, B.
    Giobbie-Hurder, A.
    Colleoni, M.
    Jensen, M-B
    Ejlertsen, B.
    de Azambuja, E.
    Neven, P.
    Lang, I.
    Gladieff, L.
    Bonnefoi, H.
    Harvey, V. J.
    Spazzapan, S.
    Tondini, C.
    Price, K.
    Piccart-Gebhart, M.
    Regan, M. M.
    Gelber, R. D.
    Coates, A. S.
    Goldhirsch, A.
    CANCER RESEARCH, 2017, 77
  • [27] Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
    Mauriac, L.
    Keshaviah, A.
    Debled, M.
    Mouridsen, H.
    Forbes, J. F.
    Thuerlimann, B.
    Paridaens, R.
    Monnier, A.
    Lang, I.
    Wardley, A.
    Nogaret, J.-M.
    Gelber, R. D.
    Castiglione-Gertsch, M.
    Price, K. N.
    Coates, A. S.
    Smith, I.
    Viale, G.
    Rabaglio, M.
    Zabaznyi, N.
    Goldhirsch, A.
    ANNALS OF ONCOLOGY, 2007, 18 (05) : 859 - 867
  • [28] Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
    Munzone, E.
    Giobbie-Hurder, A.
    Gusterson, B. A.
    Mallon, E.
    Viale, G.
    Thurlimann, B.
    Ejlertsen, B.
    MacGrogan, G.
    Bibeau, F.
    Lelkaitis, G.
    Price, K. N.
    Gelber, R. D.
    Coates, A. S.
    Goldhirsch, A.
    Colleoni, M.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2442 - 2449
  • [29] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
    Gil J.M.
    Rubio-Terrés C.
    del Castillo-Saiz A.
    González P.
    Canorea F.
    Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
  • [30] Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.
    Leone, Jose Pablo
    Cole, Bernard F.
    Regan, Meredith M.
    Thurlimann, Beat J. K.
    Coates, Alan S.
    Goldhirsch, Aron
    Di Leo, Angelo
    Colleoni, Marco
    Luis, Ines Maria Vaz Duarte
    Lin, Nancy U.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345